MAP Kinase Interacting Serine/Threonine Protein Kinase 1 (MAP Kinase Signal Integrating Kinase 1 or MKNK1 or EC 2.7.11.1) – Pipeline Review, H2 2016

Global Markets Direct’s, ‘MAP Kinase Interacting Serine/Threonine Protein Kinase 1 (MAP Kinase Signal Integrating Kinase 1 or MKNK1 or EC 2.7.11.1) – Pipeline Review, H2 2016’, provides in depth analysis on MAP Kinase Interacting Serine/Threonine Protein Kinase 1 (MAP Kinase Signal Integrating Kinase 1 or MKNK1 or EC 2.7.11.1) targeted pipeline therapeutics.

The report provides comprehensive information on the MAP Kinase Interacting Serine/Threonine Protein Kinase 1 (MAP Kinase Signal Integrating Kinase 1 or MKNK1 or EC 2.7.11.1) , targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in MAP Kinase Interacting Serine/Threonine Protein Kinase 1 (MAP Kinase Signal Integrating Kinase 1 or MKNK1 or EC 2.7.11.1) targeted therapeutics development and features dormant and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note:

Certain sections in the report may be removed or altered based on the availability and relevance of data.

Updated report will be delivered in 48 hours of order confirmation.

Scope

The report provides a snapshot of the global therapeutic landscape for MAP Kinase Interacting Serine/Threonine Protein Kinase 1 (MAP Kinase Signal Integrating Kinase 1 or MKNK1 or EC 2.7.11.1)

The report reviews MAP Kinase Interacting Serine/Threonine Protein Kinase 1 (MAP Kinase Signal Integrating Kinase 1 or MKNK1 or EC 2.7.11.1) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources

The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages

The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities

The report reviews key players involved in MAP Kinase Interacting Serine/Threonine Protein Kinase 1 (MAP Kinase Signal Integrating Kinase 1 or MKNK1 or EC 2.7.11.1) targeted therapeutics and enlists all their major and minor projects

The report assesses MAP Kinase Interacting Serine/Threonine Protein Kinase 1 (MAP Kinase Signal Integrating Kinase 1 or MKNK1 or EC 2.7.11.1) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type

The report summarizes all the dormant and discontinued pipeline projects

The report reviews latest news and deals related to MAP Kinase Interacting Serine/Threonine Protein Kinase 1 (MAP Kinase Signal Integrating Kinase 1 or MKNK1 or EC 2.7.11.1) targeted therapeutics

Reasons to buy

Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies

Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

Identify and understand the targeted therapy areas and indications for MAP Kinase Interacting Serine/Threonine Protein Kinase 1 (MAP Kinase Signal Integrating Kinase 1 or MKNK1 or EC 2.7.11.1)

Identify the use of drugs for target identification and drug repurposing

Identify potential new clients or partners in the target demographic

Develop strategic initiatives by understanding the focus areas of leading companies

Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics

Devise corrective measures for pipeline projects by understanding MAP Kinase Interacting Serine/Threonine Protein Kinase 1 (MAP Kinase Signal Integrating Kinase 1 or MKNK1 or EC 2.7.11.1) development landscape

Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Companies mentioned

eFFECTOR Therapeutics, Inc.

Eli Lilly and Company

Oncodesign SA

Table of Contents

Table of Contents

Table of Contents 2

List of Tables 4

List of Figures 4

Introduction 5

Global Markets Direct Report Coverage 5

MAP Kinase Interacting Serine/Threonine Protein Kinase 1 (MAP Kinase Signal Integrating Kinase 1 or MKNK1 or EC

2.7.11.1) Overview 6

Therapeutics Development 7

MAP Kinase Interacting Serine/Threonine Protein Kinase 1 (MAP Kinase Signal Integrating Kinase 1 or MKNK1 or EC

2.7.11.1) - Products under Development by Stage of Development 7

MAP Kinase Interacting Serine/Threonine Protein Kinase 1 (MAP Kinase Signal Integrating Kinase 1 or MKNK1 or EC

2.7.11.1) - Products under Development by Therapy Area 8

MAP Kinase Interacting Serine/Threonine Protein Kinase 1 (MAP Kinase Signal Integrating Kinase 1 or MKNK1 or EC

2.7.11.1) - Products under Development by Indication 9

MAP Kinase Interacting Serine/Threonine Protein Kinase 1 (MAP Kinase Signal Integrating Kinase 1 or MKNK1 or EC

2.7.11.1) - Pipeline Products Glance 10

Late Stage Products 10

Early Stage Products 11

MAP Kinase Interacting Serine/Threonine Protein Kinase 1 (MAP Kinase Signal Integrating Kinase 1 or MKNK1 or EC

2.7.11.1) - Products under Development by Companies 12

MAP Kinase Interacting Serine/Threonine Protein Kinase 1 (MAP Kinase Signal Integrating Kinase 1 or MKNK1 or EC

2.7.11.1) - Products under Development by Universities/Institutes 14

MAP Kinase Interacting Serine/Threonine Protein Kinase 1 (MAP Kinase Signal Integrating Kinase 1 or MKNK1 or EC

2.7.11.1) - Therapeutics Assessment 16

Assessment by Monotherapy/Combination Products 16

Assessment by Mechanism of Action 17

Assessment by Route of Administration 18

Assessment by Molecule Type 19

MAP Kinase Interacting Serine/Threonine Protein Kinase 1 (MAP Kinase Signal Integrating Kinase 1 or MKNK1 or EC

2.7.11.1) - Companies Involved in Therapeutics Development 20

eFFECTOR Therapeutics, Inc. 20

Eli Lilly and Company 21

Oncodesign SA 22

MAP Kinase Interacting Serine/Threonine Protein Kinase 1 (MAP Kinase Signal Integrating Kinase 1 or MKNK1 or EC

2.7.11.1) - Drug Profiles 23

cercosporamide - Drug Profile 23

Product Description 23

Mechanism Of Action 23

R&D Progress 23

eFT-508 - Drug Profile 25

Product Description 25

Mechanism Of Action 25

R&D Progress 25

ETC-027 - Drug Profile 27

Product Description 27

Mechanism Of Action 27

R&D Progress 27

ETC-17804452 - Drug Profile 28

Product Description 28

Mechanism Of Action 28

R&D Progress 28

ETC-219 - Drug Profile 29

Product Description 29

Mechanism Of Action 29

R&D Progress 29

Small Molecules to Inhibit MKNK1 and MKNK2 for Oncology and Unspecified Indication - Drug Profile 30

Product Description 30

Mechanism Of Action 30

R&D Progress 30

Small Molecules to Inhibit MNK1 and MNK2 for Oncology - Drug Profile 31

Product Description 31

Mechanism Of Action 31

R&D Progress 31

MAP Kinase Interacting Serine/Threonine Protein Kinase 1 (MAP Kinase Signal Integrating Kinase 1 or MKNK1 or EC

2.7.11.1) - Dormant Projects 32

MAP Kinase Interacting Serine/Threonine Protein Kinase 1 (MAP Kinase Signal Integrating Kinase 1 or MKNK1 or EC

2.7.11.1) - Featured News & Press Releases 33

Mar 18, 2016: eFFECTOR Therapeutics to Present at the American Association for Cancer Research 2016 Annual Meeting 33

Jun 19, 2015: Peer-Reviewed Study in Cell Validates eFFECTOR Therapeutics' Novel Small-Molecule Approach to Cancer Treatment 33

Jan 06, 2015: eFFECTOR Therapeutics Initiates Dosing in Phase 1/2 Clinical Trial of eFT508 in Solid Tumors 34

Appendix 35

Methodology 35

Coverage 35

Secondary Research 35

Primary Research 35

Expert Panel Validation 35

Contact Us 35

Disclaimer 36

List of Tables

List of Tables

Number of Products under Development for, H2 2016 7

Number of Products under Development by Therapy Area, H2 2016 8

Number of Products under Development by Indication, H2 2016 9

Comparative Analysis by Late Stage Development, H2 2016 10

Comparative Analysis by Early Stage Products, H2 2016 11

Number of Products under Development by Companies, H2 2016 12

Products under Development by Companies, H2 2016 13

Number of Products under Investigation by Universities/Institutes, H2 2016 14

Products under Investigation by Universities/Institutes, H2 2016 15

Assessment by Monotherapy/Combination Products, H2 2016 16

Number of Products by Stage and Mechanism of Action, H2 2016 17

Number of Products by Stage and Route of Administration, H2 2016 18

Number of Products by Stage and Molecule Type, H2 2016 19

Pipeline by eFFECTOR Therapeutics, Inc., H2 2016 20

Pipeline by Eli Lilly and Company, H2 2016 21

Pipeline by Oncodesign SA, H2 2016 22

Dormant Projects, H2 2016 32

List of Figures

List of Figures

Number of Products under Development for, H2 2016 7

Number of Products under Development by Therapy Area, H2 2016 8

Number of Products under Development by Indication, H2 2016 9

Comparative Analysis by Early Stage Products, H2 2016 11

Assessment by Monotherapy/Combination Products, H2 2016 16

Number of Products by Stage and Mechanism of Actions, H2 2016 17

Number of Products by Stage and Routes of Administration, H2 2016 18

Number of Products by Stage and Molecule Type, H2 2016 19

    Pricing

Discounts available for multiple purchases.

reportstore@globalmarketsdirect.com
+44 20 7947 2745

Saved reports